Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Clinical trial NCT00522990 · TERMINATED

Trial details

NCT number: NCT00522990
Sponsor: Astex Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Myelodysplastic Syndromes Myelofibrosis

Start date: 2006-09-01
Primary completion: 2009-04-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.